SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA

SG Americas Securities LLC boosted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 2,271.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 781,474 shares of the company’s stock after buying an additional 748,525 shares during the period. SG Americas Securities LLC owned approximately 0.29% of Taysha Gene Therapies worth $4,298,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. ST Germain D J Co. Inc. grew its stake in shares of Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after acquiring an additional 4,333 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies during the 3rd quarter valued at $40,000. Marex Group plc bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at $29,000. E Fund Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at $31,000. Finally, Allegheny Financial Group acquired a new stake in Taysha Gene Therapies in the 3rd quarter worth $49,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Trading Down 3.6%

Shares of TSHA stock opened at $4.31 on Thursday. The firm has a fifty day moving average of $4.56 and a 200-day moving average of $4.62. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -12.68 and a beta of 1.02. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $6.02. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. On average, equities research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, CFO Kamran Alam sold 23,849 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $109,943.89. Following the completion of the transaction, the chief financial officer directly owned 1,443,786 shares of the company’s stock, valued at approximately $6,655,853.46. This represents a 1.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Sean P. Nolan sold 41,312 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the transaction, the chief executive officer owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. This trade represents a 1.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 598,623 shares of company stock valued at $2,822,188. 3.78% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on TSHA. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Wells Fargo & Company lifted their target price on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Chardan Capital restated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Wall Street Zen raised Taysha Gene Therapies from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $11.09.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.